At the time of writing, Biogen Inc [BIIB] stock is trading at $154.05, down -3.65%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BIIB shares have gain 11.21% over the last week, with a monthly amount glided 9.51%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on September 25, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $190. On April 28, 2025, downgrade downgraded it’s rating to Hold but maintained its price target of $118 on the stock. Argus downgraded its rating to a Hold. Bernstein initiated its recommendation with a Mkt Perform and recommended $160 as its price target on February 11, 2025. Piper Sandler downgraded its rating to Neutral for this stock on January 02, 2025, and downed its price target to $138. In a note dated December 20, 2024, BMO Capital Markets downgraded an Market Perform rating on this stock and revised its target price from $230 to $164.
For the past year, the stock price of Biogen Inc fluctuated between $110.04 and $194.13. Currently, Wall Street analysts expect the stock to reach $182.6 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $154.05 at the most recent close of the market. An investor can expect a potential return of 18.53% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
According to Biogen Inc [NASDAQ:BIIB], the company’s sales were 9.61B for trailing twelve months, which represents an 8.86% jump. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.09 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 151.53 points at the first support level, and at 149.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 158.13, and for the 2nd resistance point, it is at 162.22.
Ratios To Look Out For
It is important to note that Biogen Inc [NASDAQ:BIIB] has a current ratio of 2.50. Also, the Quick Ratio is 1.79, while the Cash Ratio stands at 0.87. Considering the valuation of this stock, the price to sales ratio is 2.35, the price to book ratio is 1.28 and price to earnings (TTM) ratio is 14.74.
Transactions by insiders
Recent insider trading involved Singhal Priya, Head of Development, that happened on Sep 02 ’25 when 517.0 shares were sold. Officer, Singhal Priya completed a deal on Sep 02 ’25 to buy 517.0 shares. Meanwhile, Head of Global Product Strat. Izzar Rachid sold 2223.0 shares on Jul 08 ’25.
